Phase I Trial at RAH Meets Safety & Cancer Marker End Points
150723_Phase I Trial at RAH Meets Safety & Cancer Marker End Points
150723_Phase I Trial at RAH Meets Safety & Cancer Marker End Points
150716_First Two Canines Complete Combination Therapy With PPL-1
150828_Appendix 4G & Corporate Governance Statement
150828_Appendix 4E & Full Year Statutory Accounts
150728_Appendix 4C – Quarterly Report & Company Update
150624_PharmAust Receives ATO Research & Development Rebate
150617_PharmAust Initiates Combination Therapy Evaluations in Dogs
160616_ Epichem Successful in AusTrade Grant